Publications by authors named "E Berard"
According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over other regimen. In this retrospective study, we compared the efficacy of mini-consolidations (idarubicin 8 mg/m day 1, cytarabine 50 mg/m/12 h, day 1-5) and IDAC.
View Article and Find Full Text PDFIntroduction: Degenerative meniscal lesions (DML) are frequent in the general population. However, the management of stable DML is always a challenge due to the lack of universal consensus and evidence.
Hypothesis: We assessed ultrasound-guided corticosteroids medial meniscal-wall infiltration as a conservative therapy for symptomatic DML and we searched for associated factors of very good response.
Article Synopsis
- The study investigates the link between social deprivation and the incidence of kidney replacement therapy (KRT) among children and young adults in France, showing a correlation between higher social deprivation and increased KRT rates.
- Analyzed data from 2010 to 2015, including 672 children who started KRT, revealing that 38.8% were from the most deprived areas, with higher incidence rates as deprivation increased.
- Results indicate that social health inequalities emerge even at the initiation of KRT, emphasizing the importance of addressing these inequalities in chronic kidney disease management.
Article Synopsis
- Acute myeloid leukemia (AML) with BCR::ABL1 is classified as an adverse-risk group in the 2022 ELN classification, but its outcomes with modern treatment options like tyrosine kinase inhibitors are not well understood.
- In a study of 20 patients with de novo BCR::ABL1 AML from a large registry, most received standard chemotherapy with imatinib, leading to a high complete remission rate of 94.4%.
- The survival rates suggest BCR::ABL1 AML patients have better outcomes than those classified in traditional adverse-risk categories, indicating they may need reclassification in future treatment guidelines.